UNION CITY, Calif., Jan. 6 /PRNewswire-FirstCall/ -- ABAXIS, Inc. , a medical products company manufacturing point-of-care blood analysis systems, today announced the launch of the VetScan VS2(TM) the next generation in-clinic veterinary diagnostic chemistry, electrolytes, immunoassay and blood gas instrument with uncompromising accuracy from two drops of blood.
(Photo: http://www.newscom.com/cgi-bin/prnh/20060106/LAF029 )
The newly designed VetScan VS2(TM) is simple, intuitive and easy to navigate. The VetScan VS2(TM) is a smaller platform than ever before, with the capability to run rotors in as few as ten minutes. It has the ability to measure every sample for hemolysis, lipemia or icterus while accommodating the advancing technologies for new rotors currently under development. The VetScan VS2(TM) uses proprietary Intelligent Quality Control (iQC) and is based around a high-resolution full color touch screen that enables the user to view test results with the flexibility to test multiple species. This design also offers simple menu-driven choices to allow users to quickly and easily change instrument settings, select from five different languages, input customized species reference ranges, as well as perform a variety of other tasks.
VetScan(R) reagents are conveniently packaged in single use plastic rotors. Each reagent rotor contains a diluent and all the reagents necessary to perform a complete diagnostic work up including electrolytes. Other rotors are available for monitoring the critically ill, routine wellness screening, pre-anesthetic testing, thyroid health screening, liver function testing and monitoring. The rotors are designed for use with canine, feline, equine, bovine and exotic species.
Dr. Craig Tockman, DVM, a practicing veterinarian in St. Louis, Missouri, said, “The VetScan VS2(TM) and the VetScan HM2(TM) systems provide my practice with invaluable tools for immediate diagnostics as well as routine testing. With its streamlined size, the VetScan VS2(TM) maintains a small footprint and doesn’t require much bench-top space. The simple flexibility built into the instrument allows me and my staff to run any required test on multiple species, regardless of size or blood volume, which is vital in our smaller patients. Rapid results allow us to diagnose and begin treatment during one office visit leading to better medical care, and quite frequently, a better outcome. Our clients greatly appreciate the speed at which we can diagnose their pet’s conditions. The new VetScan VS2(TM) system is user-friendly, highly accurate and considerably more cost effective than other instruments on the market.”
Clint Severson, chairman and chief executive officer of Abaxis, said, “We are very excited about the introduction of the VetScan VS2(TM). We believe that the VS2(TM) represents the next generation in veterinary diagnostic equipment with an advanced user interface, complete portability, expanded printing capabilities and precision reference laboratory quality results from 100 ul of whole blood in minutes. The system enhances the ability of veterinarians to diagnose health issues in real-time during the pet visit by providing information previously unavailable in-clinic.”
Valerie Goodwin, director of marketing -- veterinary medicine at Abaxis, said, “Since its inception, the VetScan(R) product line has been about providing veterinarians the tools to deliver the best and most timely healthcare possible to their pet owner clients. People have very strong connections to their cherished pets and want to assure their well-being and happiness to the maximum extent possible. Over the years VetScan(R) has proven to be an invaluable tool in providing veterinarians the necessary diagnostics to maintain, or regain, the health and well-being of the pets that are entrusted to them. We are pleased to be able to expand the functionality, the timeliness and the effectiveness of this important next generation instrument.”
About ABAXIS
ABAXIS develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 6.9-kilogram (10.5 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs, that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in minutes with superior precision and accuracy equivalent to a clinical laboratory analyzer.
This press release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). ABAXIS claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward- looking statements are often characterized by the terms “may”, “believes”, “projects”, “expects”, or “anticipates”, and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to, risks and uncertainties related to fluctuations in the Company’s share price, the market acceptance of the Company’s products and the continuing development of its products, required United States Food and Drug Administration (“FDA”) clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with entering the human diagnostic market on a larger scale, risks related to the protection of the Company’s intellectual property or claims of infringement of intellectual property asserted by third parties, risks involved in carrying of inventory, risks associated with the ability to attract, train and retain competent sales personnel, general market conditions, competition and other risks detailed from time to time in ABAXIS’ periodic reports filed with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statement was made. ABAXIS does not undertake and specifically disclaims any obligation to update any forward-looking statements.
Contact: Clint Severson Lytham Partners, LLC Chief Executive Officer Joe Dorame, Robert Blum, Joe Diaz ABAXIS, Inc. 602-889-9700 510-675-6500
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20060106/LAF029AP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comABAXIS, Inc.
CONTACT: Clint Severson, Chief Executive Officer of ABAXIS, Inc.,+1-510-675-6500; or Joe Dorame, or Robert Blum, or Joe Diaz, all of LythamPartners, LLC, +1-602-889-9700, for ABAXIS, Inc.
